tetano
Editor, Senior Moderator
Semin Thromb Hemost
. 2024 Sep 30.
doi: 10.1055/s-0044-1790603. Online ahead of print. Vascular Pathogenesis in Acute and Long COVID: Current Insights and Therapeutic Outlook
Arneaux Kruger[SUP] 1 [/SUP], David Joffe[SUP] 2 3 [/SUP], Graham Lloyd-Jones[SUP] 4 [/SUP], Muhammed Asad Khan[SUP] 3 5 [/SUP], Špela Šalamon[SUP] 3 [/SUP], Gert J Laubscher[SUP] 6 [/SUP], David Putrino[SUP] 2 7 [/SUP], Douglas B Kell[SUP] 1 8 9 [/SUP], Etheresia Pretorius[SUP] 1 3 8 [/SUP]
Affiliations
Long coronavirus disease 2019 (COVID-19)-a postacute consequence of severe acute respiratory syndrome coronavirus 2 infection-manifests with a broad spectrum of relapsing and remitting or persistent symptoms as well as varied levels of organ damage, which may be asymptomatic or present as acute events such as heart attacks or strokes and recurrent infections, hinting at complex underlying pathogenic mechanisms. Central to these symptoms is vascular dysfunction rooted in thrombotic endothelialitis. We review the scientific evidence that widespread endothelial dysfunction (ED) leads to chronic symptomatology. We briefly examine the molecular pathways contributing to endothelial pathology and provide a detailed analysis of how these cellular processes underpin the clinical picture. Noninvasive diagnostic techniques, such as flow-mediated dilation and peripheral arterial tonometry, are evaluated for their utility in identifying ED. We then explore mechanistic, cellular-targeted therapeutic interventions for their potential in treating ED. Overall, we emphasize the critical role of cellular health in managing Long COVID and highlight the need for early intervention to prevent long-term vascular and cellular dysfunction.
. 2024 Sep 30.
doi: 10.1055/s-0044-1790603. Online ahead of print. Vascular Pathogenesis in Acute and Long COVID: Current Insights and Therapeutic Outlook
Arneaux Kruger[SUP] 1 [/SUP], David Joffe[SUP] 2 3 [/SUP], Graham Lloyd-Jones[SUP] 4 [/SUP], Muhammed Asad Khan[SUP] 3 5 [/SUP], Špela Šalamon[SUP] 3 [/SUP], Gert J Laubscher[SUP] 6 [/SUP], David Putrino[SUP] 2 7 [/SUP], Douglas B Kell[SUP] 1 8 9 [/SUP], Etheresia Pretorius[SUP] 1 3 8 [/SUP]
Affiliations
- PMID: 39348850
- DOI: 10.1055/s-0044-1790603
Long coronavirus disease 2019 (COVID-19)-a postacute consequence of severe acute respiratory syndrome coronavirus 2 infection-manifests with a broad spectrum of relapsing and remitting or persistent symptoms as well as varied levels of organ damage, which may be asymptomatic or present as acute events such as heart attacks or strokes and recurrent infections, hinting at complex underlying pathogenic mechanisms. Central to these symptoms is vascular dysfunction rooted in thrombotic endothelialitis. We review the scientific evidence that widespread endothelial dysfunction (ED) leads to chronic symptomatology. We briefly examine the molecular pathways contributing to endothelial pathology and provide a detailed analysis of how these cellular processes underpin the clinical picture. Noninvasive diagnostic techniques, such as flow-mediated dilation and peripheral arterial tonometry, are evaluated for their utility in identifying ED. We then explore mechanistic, cellular-targeted therapeutic interventions for their potential in treating ED. Overall, we emphasize the critical role of cellular health in managing Long COVID and highlight the need for early intervention to prevent long-term vascular and cellular dysfunction.